Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT)

Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $1.4M; returns 1 day -36.7%, 1 week -46.6%.

Lakewood-Amedex Biotherapeutics Inc. is a clinical-stage biotechnology company specializing in the development of a novel class of synthetic antimicrobials known as Bisphosphocins®. The company's lead drug candidate, Nu-3, is a topical gel currently advancing through Phase 2 clinical trials specifically for the treatment of mildly infected diabetic foot ulcers (iDFU).

Groups LABT belongs to

• Recent Reverse Splits
• Recent IPOs
• Biotechnology
• Clinical Stage Biopharma
• Clinical Stage
• Pharmaceuticals
• Infectious Diseases
• Healthcare
• Antivirals
• Unmet Medical Needs
• R&D

LABT financial model: income statement, cash flow and balance sheet